ImmunityBio, Inc. Stock price

Equities

IBRX

US45256X1037

Biotechnology & Medical Research

Delayed Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
5.37 USD -1.65% Intraday chart for ImmunityBio, Inc. -12.97% +6.97%
Sales 2024 * 9.68M Sales 2025 * 84.68M Capitalization 3.62B
Net income 2024 * -459M Net income 2025 * -305M EV / Sales 2024 * 374 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 42.7 x
P/E ratio 2024 *
-7.9 x
P/E ratio 2025 *
-11.9 x
Employees 628
Yield 2024 *
-
Yield 2025 *
-
Free-Float 20.33%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on ImmunityBio, Inc.

1 day-1.65%
1 week-12.97%
Current month+13.53%
1 month+18.02%
3 months+3.07%
6 months+235.62%
Current year+6.97%
More quotes
1 week
4.59
Extreme 4.59
6.23
1 month
4.49
Extreme 4.49
6.78
Current year
3.12
Extreme 3.12
6.78
1 year
1.25
Extreme 1.25
6.93
3 years
1.21
Extreme 1.21
25.62
5 years
1.21
Extreme 1.21
40.83
10 years
1.21
Extreme 1.21
40.83
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 20-09-30
Founder 71 14-11-30
Director of Finance/CFO 46 19-06-30
Members of the board TitleAgeSince
Founder 71 14-11-30
Director/Board Member 58 19-05-31
Director/Board Member 78 21-02-23
More insiders
Date Price Change Volume
24-03-28 5.37 -1.65% 4,630,603
24-03-27 5.46 +6.64% 5,237,370
24-03-26 5.12 -5.88% 2,950,073
24-03-25 5.44 -10.38% 4,439,565
24-03-22 6.07 -1.62% 5,266,643

Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT

More quotes
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its proprietary platforms that amplify both the innate and adaptive branches of the immune system, its advances therapies and vaccines to defeat urologic and other cancers, as well as infectious diseases. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising, B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA and recombinant protein vaccines, and cell therapies. Its lead biologic commercial product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
5.37 USD
Average target price
5 USD
Spread / Average Target
-6.89%
Consensus
  1. Stock
  2. Equities
  3. Stock ImmunityBio, Inc. - Nasdaq